Vigil Neuroscience reports Q1 net loss $19.9M; completes enrollment for Phase 2 ALSP trial, data in Q3 2024

Vigil Neuroscience, Inc.

2024-Q1 EPS reported -$0.50

Cash, cash equivalents & marketable securities $101.6M as of Mar 31, 2024; expected to fund operations into H2 2025.
Completed enrollment for Phase 2 IGNITE trial of iluzanebart in ALSP with 20 patients, exceeding planned 15.
Next data readout from Phase 2 IGNITE planned for Q3 2024, including 12-month data from 20 mg/kg cohort and 6-month from 40 mg/kg.
Phase 1 trial of VG-3927 for Alzheimer's ongoing; interim healthy volunteer data expected mid-2024.
Appointed Petra Kaufmann as Chief Medical Officer; she brings over 25 years of neurology drug development experience.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vigil Neuroscience, Inc. reported First quarter ended March 31, 2024 results: net income Loss from operations for the first quarter ended March 31, 2024 were $19.9 million.

Period: First quarter ended March 31, 2024
Net income: Loss from operations for the first quarter ended March 31, 2024 were $19.9 million
Result: reported results

Exact text from the filing

Loss from operations for the first quarter ended March 31, 2024 were $19.9 million, compared to $19.8 million for the same period in 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-133141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.